Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Lee S. Schwartzberg, MD, on Clinical Challenges of Using Tesetaxel and Capecitabine in the Treatment of HER2– HR+ Breast Cancer

Posted: Wednesday, December 16, 2020

Lee S. Schwartzberg, MD, of the West Cancer Center, offers an expert perspective on the clinical challenges featured in the phase III CONTESSA trial, which suggested advantages to the oral formulation of tesetaxel plus a reduced dose of capecitabine vs capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.